Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Joanna Kosałka-Węgiel, Sabina Lichołai, Renata Pacholczak-Madej, Sylwia Dziedzina, Mamert Milewski, Piotr Kuszmiersz, Anna Korona, Jolanta Gąsior, Aleksandra Matyja-Bednarczyk, Helena Kwiatkowska, Lech Zaręba, Andżelika Siwiec-Koźlik, Paweł Koźlik-Siwiec, Anita Wach, Weronika Pociej-Marciak, Marek Sanak, Jacek Musiał, Stanisława Bazan-Socha, Mariusz Korkosz
Recent reports have demonstrated that endothelial injury is critical in the pathogenesis of systemic sclerosis (SSc) and is associated with increased levels of circulating inflammatory biomarkers. This study aims to analyze the serum concentrations of selected cytokines and evaluate their relationship with SSc clinics and the long-term course of the disease. This study included 43 SSc patients and 24 matched healthy controls. In both groups, we measured serum levels of inflammatory cytokines related to the inflammatory response, such as tumor necrosis factor (TNF)α, interferon (IFN)γ, interleukin (IL)-4, IL-6, IL-10, and IL-17, and fibroblast activation protein (FAP)...
December 5, 2023: Rheumatology International
#22
JOURNAL ARTICLE
Pellegrino Musto, Jon Salmanton-García, Nicola Sgherza, Rui Bergantim, Francesca Farina, Andreas Glenthøj, Guldane Cengiz Seval, Barbora Weinbergerová, Valentina Bonuomo, Yavuz M Bilgin, Jaap van Doesum, Ozren Jaksic, Benjamín Víšek, Iker Falces-Romero, Monia Marchetti, Julio Dávila-Valls, Sonia Martín-Pérez, Marcio Nucci, Alberto López-García, Federico Itri, Caterina Buquicchio, Luisa Verga, Klára Piukovics, Milan Navrátil, Graham P Collins, Moraima Jiménez, Nicola S Fracchiolla, Jorge Labrador, Lucia Prezioso, Elena Rossi, Natasha Čolović, Stef Meers, Austin Kulasekararaj, Annarosa Cuccaro, Ola Blennow, Toni Valković, Uluhan Sili, Marie-Pierre Ledoux, Josip Batinić, Francesco Passamonti, Marina Machado, Rafael F Duarte, Christian Bjørn Poulsen, Gustavo-Adolfo Méndez, Ildefonso Espigado, Fatih Demirkan, Martin Čerňan, Chiara Cattaneo, Verena Petzer, Gabriele Magliano, Carolina Garcia-Vidal, Shaimaa El-Ashwah, Maria Gomes-Da-Silva, Antonio Vena, Irati Ormazabal-Vélez, Jens van Praet, Michelina Dargenio, Cristina De-Ramón, Maria Ilaria Del Principe, Joyce Marques-De-Almeida, Dominik Wolf, Tomáš Szotkowski, Aleš Obr, Gökçe Melis Çolak, Anna Nordlander, Macarena Izuzquiza, Alba Cabirta, Giovanni Paolo Maria Zambrotta, Raul Cordoba, Pavel Žák, Emanuele Ammatuna, Jiří Mayer, Osman Ilhan, Ramón García-Sanz, Martina Quattrone, Elena Arellano, Raquel Nunes-Rodrigues, Ziad Emarah, Tommaso Francesco Aiello, Michaela Hanakova, Zdeněk Ráčil, Martina Bavastro, Alessandro Limongelli, Laman Rahimli, Francesco Marchesi, Oliver A Cornely, Livio Pagano
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world...
December 4, 2023: Hematological Oncology
#23
JOURNAL ARTICLE
Lama M Almuhaysen, Amal Badr Abu Al Alaa
BACKGROUND: Renal impairment, often occurring as a result of multiple myeloma, poses a significant risk to patient health and quality of life. Therefore, the study was conducted with the objective of investigating the management of renal failure in patients diagnosed with multiple myeloma in Saudi Arabia. METHODS: A retrospective observational study was conducted during the period from January to August 2023 for the duration of eight months. The data were collected from the patients diagnosed with multiple myeloma, available from the medical records of Prince Sultan Military Medical City, Saudi Arabia...
October 2023: Curēus
#24
JOURNAL ARTICLE
Sushmita Khadka, Swetha Balaji, Japjeet Kaur, Dhanshree Solanki, Mariia Kasianchyk, Humayra Chowdhury, Ishani Patel, Muhammad Qasim, Maheshkumar Desai, Prakash Maiyani, Dharmeshkumar V Moradiya, Darshan Lal, Achint A Patel, Manidhar Lekkala
Background With the advent of novel treatments, there is a declining trend in the multiple myeloma (MM) mortality rate with an increasing hospitalization rate. However, there is limited population-based data on trends and outcomes of hospitalizations due to MM in the United States (US). Methods We analyzed the publicly available Nationwide Inpatient Sample (NIS) from 2007 to 2017 to identify MM hospitalizations. Results Hospitalizations for MM increased from 17,100 (8.71%) in 2007 to 19,490 (9.92%) in 2017...
October 2023: Curēus
#25
S Rajkumar, Nadine Abdallah, Arjun Lakshman, Shaji Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie Gertz, Martha Lacy, Suzanne Hayman, Francis Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, P Leif Bergsagel
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification...
October 23, 2023: Research Square
#26
JOURNAL ARTICLE
Laurent Garderet, Hafida Ouldjeriouat, Mohamed-Amine Bekadja, Elisabeth Daguenet, Noemie Bigot, Laure Vincent, Damien Roos-Weil, Marguerite Vignon, Souhila Ikhlef, Julie Abraham, Martine Escoffre-Barbe, Bruno Lioure, Redhouane Ahmed Nacer, Ingrid Lafon, Clara Mariette, Lionel Karlin, Pierre Morel, Lila Gilis, Emanuelle Le Ray, Anaïse Blouet, Stéphanie Nguyen Quoc, Jean Jacques Boffa, Pierre Ronco, Jerome Lambert, Jérôme Cornillon
High-dose melphalan followed by autologous haematopoietic stem cell transplantation is widely used in newly diagnosed multiple myeloma (MM) patients as upfront therapy. However, the safety and efficacy of transplantation in patients with renal insufficiency (RI) are controversial. We followed a multicentre (16 SFGM-TC centres) prospective cohort of 50 newly diagnosed MM patients with a serum creatinine clearance of <40 mL/min at transplantation. Patients received a recommended dose of melphalan of 140 mg/m2 ...
November 12, 2023: British Journal of Haematology
#27
JOURNAL ARTICLE
Vijayakumar Karthik, Rameez Roshan, Puthiyaveetil Khadar Jabbar, Abilash Nair
The case report describes the details of a man in his 40s admitted for evaluation of renal failure. Biochemical testing revealed parathyroid hormone (PTH) -independent hypercalcaemia. The evaluations for the usual causes such as malignancies, granulomatous diseases, multiple myeloma and vitamin D toxicity were negative. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) scan identified diffuse uptake in the muscles, and the subsequent muscle biopsy showed non-caseating granulomas suggestive of granulomatous myositis, possibly sarcoidosis, in view of raised ACE levels and the absence of other causes...
October 17, 2023: BMJ Case Reports
#28
MULTICENTER STUDY
Danilo De Novellis, Raffaele Fontana, Salvatore Palmieri, Roberta Della Pepa, Maria Di Perna, Giusy Cetani, Daniela Esposito, Angela Amendola, Giuseppe Delle Cave, Bianca Serio, Denise Morini, Michela Rizzo, Laura Mettivier, Fabio Trastulli, Stefano Rocco, Anastasia Pagano, Serafina Barbato, Aldo Leone, Martina La Magna, Rosario Bianco, Gabriella Rascato, Angela Carobene, Bianca Cuffa, Marialuigia Iannalfo, Valentina Giudice, Gino Svanera, Mario Annunziata, Michele Pizzuti, Ferdinando Frigeri, Catello Califano, Felicetto Ferrara, Fabrizio Pane, Carmine Selleri
BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or at a subcutaneous fixed dose of 1800 mg. However, the subcutaneous formulation has only recently been approved in Europe, and real-life data on its safety are still few. OBJECTIVE: In this multicenter retrospective real-life experience, we provided evidence for the safety of subcutaneous daratumumab in plasma cell disorders...
November 2023: Targeted Oncology
#29
JOURNAL ARTICLE
Rova Malala Fandresena Randrianarisoa, Valéry Refeno, Ny Ony Tiana Florence Andrianandrasana, Fidiarivony Ralison, Hanta Marie Danielle Vololontiana, Florine Rafaramino
INTRODUCTION: In Madagascar, the epidemiologic, therapeutic, and evolutionary aspects of multiple myeloma remain poorly understood. Our objectives were to describe the cases, report factors associated with mortality, and estimate patient survival. PATIENTS AND METHOD: This was a retrospective descriptive and analytical study conducted in five teaching hospitals in Madagascar: HJRA and CENHOSOA (Antananarivo), CHUPZAGA (Mahajanga), CHUAT (Toamasina) and CHUT (Fianarantsoa)...
December 2023: Hematology (Amsterdam, Netherlands)
#30
JOURNAL ARTICLE
Christian W Schaaf, Matthias C Braunisch, Christopher Holzmann-Littig, Frederick Pfister, Liya Hannemann, Renate I Hausinger, Mareike Verbeek, Christoph Schmaderer, Lutz Renders, Uwe Heemann, Claudius Küchle
BACKGROUND: We determined the efficacy of free light chain (FLC) removal by regular dialysis equipment (high-flux filtration) with medium cutoff (MCO) membrane hemodialysis (HD) as an adjuvant treatment to standard chemotherapy for patients with acute kidney injury complicating multiple myeloma (MM) and its impact on further dialysis dependency. METHODS: Sixty patients with acute dialysis-dependent renal failure secondary to MM were treated with MCO-HD (55 patients) or HCO (high cutoff)-HD (5 patients) as a control...
2023: Frontiers in Oncology
#31
REVIEW
Munawwar Hussain, Sarvari Yellapragada, Samer Al Hadidi
Multiple myeloma (MM) is a hematologic malignancy characterized by the abnormal clonal proliferation of plasma cells that may result in focal bone lesions, renal failure, anemia, and/or hypercalcemia. Recently, the diagnosis and treatment of MM have evolved due to a better understanding of disease pathophysiology, improved risk stratification, and new treatments. The incorporation of new drugs, including proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies and high-dose chemotherapy followed by hematopoietic stem cell transplantation, has resulted in a significant improvement in patient outcomes and QoL...
2023: Blood and Lymphatic Cancer: Targets and Therapy
#32
JOURNAL ARTICLE
Anna Staskiewicz, Erica Wong, Michael Tucker, Riya Farhin, Jonathan Park, Rana Saade, Tina Alkhazali, Tu Dang, Xinyu Wang
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow characterized by bone lesions, hypercalcemia, anemia, and renal failure. Bortezomib (BTZ), a common treatment for MM, is a proteasome inhibitor that induces apoptosis in MM cells. However, high doses of BTZ can be very toxic, signifying a need for a synergistic drug combination to improve treatment efficacy. Resveratrol (RES), a phenolic compound found in grapes, has been shown to inhibit MM cell growth. We sought to identify a synergistic combination of BTZ with a RES derivative and analyze the effects on reducing viability and inducing apoptosis in human MM cells...
August 9, 2023: International Journal of Molecular Sciences
#33
REVIEW
Rachelle Gietzen, Vidarshi Muthukumarana, Peeyush Bhargava, Dmitrii Vozniuk, Beenu Thakral, L Jeffrey Medeiros, Kirill A Lyapichev
BACKGROUND: Plasmablastic lymphoma (PBL) is a rare, aggressive large B-cell lymphoma with plasmablastic or immunoblastic morphology and a terminally differentiated B-cell immunophenotype. PBL often presents at extranodal sites, commonly the oral cavity of immunocompromised patients with human immunodeficiency virus (HIV) and/or Epstein-Barr virus (EBV) infection. Cases of PBL arising outside the oral cavity in previously healthy immunocompetent patients are rare. CASE REPORT: We report a 65-year-old HIV- and EBV-negative man who presented with abdominal pain, fatigue, and vomiting...
July 29, 2023: Annals of Diagnostic Pathology
#34
Infection related membranoproliferative glomerulonephritis secondary to anaplasmosis: A case report.
Maulik K Lathiya, Praveen Errabelli, Salvatore Mignano, Susan M Cullinan
BACKGROUND: Anaplasmosis is a tick-borne disease with a range of clinical manifestations, from a flu-like illness with fever and myalgias to a severe systemic disease with multisystem organ failure. Although renal involvement is not a common presentation, there have been few cases reporting acute kidney injury from Anaplasmosis. CASE SUMMARY: We present a 55-year-old female with anaplasmosis who developed acute kidney injury due to membranoproliferative glomerulonephritis (MPGN)...
May 25, 2023: World Journal of Nephrology
#35
JOURNAL ARTICLE
Stella Bowcock, Catherine Atkin, Gulnaz Iqbal, Guy Pratt, Kwee Yong, Richard D Neal, Tim Planche, Kamaraj Karunanithi, Stephen Jenkins, Simon Stern, Sarah Arnott, Peter Toth, Farooq Wandroo, Janet Dunn, Mark T Drayson
Multiple myeloma (MM) patients risk diagnostic delays and irreversible organ damage. In those with newly diagnosed myeloma, we explored the presenting symptoms to identify early signals of MM and their relationships to organ damage. The symptoms were recorded in patients' own words at diagnosis and included diagnostic time intervals. Those seen by a haematologist >6 months prior to MM diagnosis were classified as precursor disease (PD). Most (962/977) patients provided data. Back pain (38%), other pain (31%) and systemic symptoms (28%) predominated...
June 25, 2023: Cancers
#36
JOURNAL ARTICLE
Gabriele Donati, Agnieszka Przygocka, Fulvia Zappulo, Gisella Vischini, Sabrina Valente, Gaetano La Manna
BACKGROUND: Older individuals with multiple comorbidities and especially patients with multiple myeloma are at higher risk of contracting SARS-CoV-2. When patients with multiple myeloma (MM) are also affected by SARS-CoV-2 the time to start immunosuppressants is still a clinical dilemma especially when urgent hemodialysis is required for acute kidney injury (AKI). CASE PRESENTATION: We present a case of an 80-year-old woman who was diagnosed with AKI in MM. The patient began hemodiafiltration (HDF) with free light chain removal combined with bortezomib and dexamethasone...
July 6, 2023: BMC Nephrology
#37
JOURNAL ARTICLE
Alex Guedes, Ricardo Gehrke Becker, Luiz Eduardo Moreira Teixeira
Multiple myeloma (MM) is a hematological malignancy characterized by unregulated and clonal proliferation of plasma cells in the bone marrow; these cells produce and secrete an anomalous monoclonal immunoglobulin, or a fragment of this, called M protein. The clinical manifestations of MM result from the proliferation of these plasmocytes, the excessive production of monoclonal immunoglobulin and the suppression of normal humoral immunity, leading to hypercalcemia, bone destruction, renal failure, suppression of hematopoiesis and humoral immunity, increasing the risk for the development of infections...
June 2023: Revista Brasileira de Ortopedia
#38
Nicholas J Burkholder, Lauren M Sweet, Erin L Kelly
Acute kidney failure has myriad causes and presentations. This is a case of an individual with a history of alcohol abuse and a previous suicide attempt presenting with acute kidney failure and altered mentation accompanied by an anion gap metabolic acidosis with an elevated osmolar gap. These findings were concerning for toxic alcohol ingestion, but the patient was ultimately diagnosed with multiple myeloma. This case demonstrates the multiple factors that can impact both the anion and osmolar gaps...
May 2023: Curēus
#39
JOURNAL ARTICLE
Margot Egger, Anne Black, Christoph Robier
We report the case of a 66-year-old man with a known history of IgD multiple myeloma (MM) which was admitted to hospital because of acute renal failure. Routine PCR testing on admission yielded a positive result for SARS-CoV-2 infection. Examination of the peripheral blood (PB) smear revealed 17% lymphoplasmacytoid cells and a few small plasma cells mimicking morphological changes frequently seen in viral diseases. However, flow cytometric examination showed 20% clonal lambda-restricted plasma cells being consistent with a diagnosis of secondary plasma cell leukemia...
June 2023: Journal of Hematopathology
#40
JOURNAL ARTICLE
Csilla Markóth, László Bidiga, László Váróczy, Ibolya File, József Balla, János Mátyus
In light chain amyloidosis (LA), the massive glomerular and vascular amyloid deposition leading to interstitial fibrosis/tubular atrophy (IFTA) is thought to be responsible for renal failure. The amyloid deposition in the interstitium and the tubular basement membrane (TBM) has received less attention in the study of LA. We, therefore, collected clinical and laboratory data on patients diagnosed with LA in our Nephrology Department and studied amyloid deposition in the TBM. Twelve LA patients were diagnosed by renal biopsy during a seven-year period...
December 2023: Renal Failure
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
